An article on Fortune magazine’s web site discusses Titan Pharmaceuticals (NASDAQ:TTNP) and its newest implant with a commonly used Parkinson’s disease drug called ropinirole.
Last week, the FDA gave Titan the green light to conduct clinical trials of the ropinirole implant. The implant’s steady delivery system has the potential to avoid a drop-off in symptom control of oral ropinirole, which can lead to tremors, stiffness and loss of balance.
The article can be accessed here.
